Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin
- 1 January 2003
- journal article
- review article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 3 (4), 202-214
- https://doi.org/10.1038/sj.tpj.6500182
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human dataPharmacogenetics, 2002
- Anticoagulant Therapy in Japanese Patients With Mechanical Mitral Valves.Circulation Journal, 2002
- Interindividual variability in sensitivity to warfarin-Nature or nurture?Clinical Pharmacology & Therapeutics, 2001
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial FibrillationStroke, 2000
- Oral AnticoagulantsSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1998
- Genetic association between sensitivity to warfarin and expression of CYP2C9*3Pharmacogenetics, 1997
- Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactionsChemical Research in Toxicology, 1992
- A physiological approach to hepatic drug clearanceClinical Pharmacology & Therapeutics, 1975
- Studies on the optical enantiomorphs of warfarin in manClinical Pharmacology & Therapeutics, 1974